The FATE Paradox: Analysts Bullish But Forecast -15.53% Fall
November 30, 2020 at 08:56 AM EST
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Fate Therapeutics Inc (FATE). The average 12-month price target for FATE — averaging the work of 13 analysts — reveals an average price target of $48.92/share..
